Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Up 5.30%
As of Tuesday, July 21, Tango Therapeutics, Inc.’s TNGX share price has surged by 5.30%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Up 5.30%
As of Friday, July 17, Tango Therapeutics, Inc.’s TNGX share price has surged by 5.30%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Down 5.59%
As of Thursday, July 16, Tango Therapeutics, Inc.’s TNGX share price has dipped by 5.59%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Down 5.44%
As of Monday, July 13, Tango Therapeutics, Inc.’s TNGX share price has dipped by 5.44%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or Tango Therapeutics, Inc. Stock?
Learn more about whether Ionis Pharmaceuticals, Inc. or Tango Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Financial Summary
| Share Statistics | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,933.7 | $252.6 | 64% |
|
| Shares Out (Mil) | 143.6 | 52.3 | 70% |
|
| Institutional Ownership | 98.4% | 92.1% | 79% |
|
| Float (Mil) | 69.6 | 40.2 | 54% |
|
| Beta | 1.22 | 0.95 | 71% |
|
| Avg Daily Volume (000s) | 2,238 | 455 | 84% |
|
| Price Change (52-week) |
331.7% | 52.9% | 99% |
|
| Growth | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 52.0% | 13.6% | 96% |
|
| Net Income (5yr) | (14.3%) | (9.9%) | 26% |
|
| EPS (5yr) | 11.7% | 16.0% | 50 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 16.8% | (15.6%) | 76% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 12 | 11 | |
| Current EPS | ($0.324) | ($1.294) | ($1.520) | |
| Month Ago EPS | ($0.322) | ($1.309) | ($1.580) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.329) | ($1.345) | ($1.631) | |
| Year/Year Chg | 2.2% | 47.9% | 95.0% | |
| Financials | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $57 | $38 | 21% |
|
| Net Income (TTM) (Mil) | ($107) | ($43) | 10% |
|
| EPS (TTM) | ($0.861) | ($1.600) | 23% |
|
| Operating Cash Flow (TTM) (Mil) | ($142) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $99 | $5 | 77% |
|
| Long-Term Debt (Q1) (Mil) | $30 | $5 | 35% |
|
| Enterprise Value (Q1) (Mil) | $3,250 | $180 | 56% |
|
| Valuation | TNGX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 10.00 | 2.56 | 90% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (126.8%) | 63.8% | 2% |
|
| Net Margin | (188.2%) | (67.3%) | 5% |
|
| ROA | (30.2%) | (49.8%) | 17% |
|
| ROE | (38.4%) | (55.5%) | 18% |
|
| Liabilities to Assets | 10.2% | 30.3% | 6% |
|
| F-Score | 4 | 3 | 34% |
|
Tango Therapeutics, Inc. did not pass any screens on 7/31/2026.
